Markus Britschgi, PhD, is Principal Scientist at Roche Pharma Research and Early Development, in Neuroscience Discovery at the Roche Innovation Center Basel, Switzerland, which he joined in 2009. In this role he leads the discovery and research activities around alpha-synuclein and passive immunotherapies for this target. He is also the Research Lead in the Clinical Development Team for PRX002, a humanized monoclonal antibody targeting alpha-synuclein in Parkinson’s disease (PD), which is partnered and jointly developed with Prothena Biosciences Inc, South San Francisco, USA. Britschgi’s research focuses mainly on pathways involved in alpha-synuclein pathology including systemic inflammation and its role in the accumulation of alpha-synuclein in the enteric nervous system in mice and humans. Additionally, Britschgi investigates the nature of Lewy pathology post-mortem in the brain of PD patients and supports the identification of novel translational biomarkers of PD and Alzheimer’s disease. From 2003 to 2009, Britschgi was postdoc and instructor at Stanford University and conducted research about the role of immune pathways in neurodegenerative disorders such as Alzheimer’s disease and Frontotemporal dementia and also explored protein-array based systemic biomarkers for normal aging and neurodegenerative disease. Britschgi received his PhD in Immunology in 2002 from the University of Bern, Switzerland, and performed his undergraduate and master studies in biochemistry at the University of Fribourg, Switzerland, where he graduated in 1997. Britschgi is first and senior author of original research papers published in various high impact journals and has co-authored several papers and reviews as well.